(Q46576538)

23 December 2017

title

The costs of non-muscle invasive bladder cancer (English)

1 reference

23 December 2017

author

John L Gore

series ordinal

2

1 reference

23 December 2017

author name string

Andrew C James

series ordinal

1

1 reference

23 December 2017

publication date

13 February 2013

1 reference

23 December 2017

Urologic Clinics of North America

published in

1 reference

23 December 2017

volume

40

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

261-269

1 reference

23 December 2017

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Projections of the cost of cancer care in the United States: 2010-2020.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The health economics of bladder cancer: a comprehensive review of the published literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Evaluation and follow-up strategies for superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Tobacco smoking and cancer: A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Clinical model of lifetime cost of treating bladder cancer and associated complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The use of molecular diagnostics in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Intravesical therapy for superficial bladder cancer: is it a wash?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Defining the role of NMP22 in bladder cancer surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Bladder cancer detection using FISH (UroVysion assay).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Quality of life in long-term survivors of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

The excessive cost of early stage bladder cancer care: are providers really to blame?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Adherence to Surveillance Among Patients With Superficial Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Provider treatment intensity and outcomes for patients with early-stage bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Identifying better practices for early-stage bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Partnering with payers to improve surgical quality: the Michigan plan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Washington State's approach to variability in surgical processes/Outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

Creating a learning healthcare system in surgery: Washington State's Surgical Care and Outcomes Assessment Program (SCOAP) at 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.004

10.1016/J.UCL.2013.01.004

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

23540783

1 reference

23 December 2017